Log in

NASDAQ:SNTS - Santarus Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$16,995.00
0.00 (0.00 %)
(As of 06/6/2019)
Add
Today's Range
$16,990.00
Now: $16,995.00
$16,995.00
50-Day Range
$16,995.00
MA: $16,995.00
$16,995.00
52-Week Range N/A
Volume20,041 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Santarus, Inc (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company's marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:SNTS
CUSIP80281730
Phone+1-858-3145700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive SNTS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNTS and its competitors with MarketBeat's FREE daily newsletter.


Santarus (NASDAQ:SNTS) Frequently Asked Questions

What is Santarus' stock symbol?

Santarus trades on the NASDAQ under the ticker symbol "SNTS."

Has Santarus been receiving favorable news coverage?

News headlines about SNTS stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Santarus earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Santarus.

Who are some of Santarus' key competitors?

What other stocks do shareholders of Santarus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Santarus investors own include Celgene (CELG), Baidu (BIDU), Pharmacyclics (PCYC), Home Depot (HD), Yelp (YELP), Altaba (AABA), ACADIA Pharmaceuticals (ACAD), Alexion Pharmaceuticals (ALXN), Cree (CREE) and Keurig Green Mountain (GMCR).

What is Santarus' stock price today?

One share of SNTS stock can currently be purchased for approximately $16,995.00.

What is Santarus' official website?

The official website for Santarus is http://www.santarus.com/.

How can I contact Santarus?

Santarus' mailing address is 3611 Valley Centre Dr Ste 400, SAN DIEGO, CA 92130-3331, United States. The biopharmaceutical company can be reached via phone at +1-858-3145700.


MarketBeat Community Rating for Santarus (NASDAQ SNTS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Santarus and other stocks. Vote "Outperform" if you believe SNTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel